Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rutherrin
- Development stage
- Preclinical
- Lead developer
- Theralase Technologies
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Rutherrin is an investigational, intravenously administered photodynamic and radiodynamic therapy formulation developed by Theralase Technologies. It consists of Ruvidar (TLD-1433), a ruthenium(II)-based small-molecule photosensitizer, complexed with recombinant human transferrin. The transferrin component acts as a targeting moiety, directing the complex to cancer cells that overexpress the transferrin receptor (TfR/CD71). Once internalized, Rutherrin can be activated by light or ionizing radiation (such as X-rays) to generate cytotoxic reactive oxygen species (ROS), leading to direct tumor cell destruction and the induction of immunogenic cell death (ICD). Rutherrin is currently in preclinical development for several aggressive cancers, including glioblastoma multiforme (GBM), non-small cell lung cancer (NSCLC), muscle-invasive bladder cancer (MIBC), pancreatic cancer, colorectal cancer, and lymphoma.
- Brand names
- Rutherrin
- Other names
- Ruvidar + transferrinRuvidar combined with transferrinTLD-1433 + transferrinTLD-1433 combined with transferrinTLD1433 combined with transferrinTLD 1433 combined with transferrinTLD1433 + transferrin
02
Targets
DNATFRC (Transferrin Receptor)
Beyond the preview
Go deeper on Rutherrin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rutherrin.